Compare · BYRN vs TMO
BYRN vs TMO
Side-by-side comparison of Byrna Technologies Inc. (BYRN) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- BYRN operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $257.53B, about 2301.9x BYRN ($111.9M).
- BYRN has been more active in the news (8 items in the past 4 weeks vs 7 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 11 for BYRN).
- Company
- Byrna Technologies Inc.
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $111.9M
- $257.53B
- 1M return
- -
- +4.77%
- 1Y return
- -
- +28.01%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 8
- 7
- Recent ratings
- 11
- 25
Byrna Technologies Inc.
Byrna Technologies Inc., a less-lethal defense technology company, develops and manufactures less-lethal munitions. The company offers a Byrna line of handheld personal security devices, including the Byrna HD, a .68 caliber handheld personal security device that is designed to be used by civilians and private security professionals, as well as Byrna HD magazines, launchers, and projectiles. It operates in the United States, Canada, and South Africa. The company was formerly known as Security Devices International, Inc. and changed its name to Byrna Technologies Inc. in March 2020. Byrna Technologies Inc. was incorporated in 2005 and is headquartered in Andover, Massachusetts.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest BYRN
- Amendment: SEC Form 4/A filed by Byrna Technologies Inc.
- SEC Form 4 filed by Byrna Technologies Inc.
- SEC Form 8-K filed by Byrna Technologies Inc.
- SEC Form 10-Q filed by Byrna Technologies Inc.
- Byrna Technologies Reports Fiscal Third Quarter 2026 Results
- Byrna Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Byrna Technologies Launches Media Campaign with iHeartMedia’s “The Bobby Bones Show” to Expand Mainstream Reach
- Byrna Technologies to Report Fiscal Third Quarter 2026 Financial Results on Thursday, October 8, 2026 at 9:00 a.m. ET
- SEC Form 3 filed by new insider Mcbrady Matthew R
- Amendment: SEC Form SCHEDULE 13D/A filed by Byrna Technologies Inc.
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)